CXCR7-agonist administration reduces platelet degranulation, αIIbβ3-integrin activation and thrombotic propensity 24 h post-MI; it also counteracts thrombus build-up, prolonging time to vessel occlusion following FeCl3-inflicted carotid artery injury. This evidence concerns the gene ACKR3 and myocardial infarction.